Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide.

Clinical pharmacology and therapeutics - 1 Dec 2004

Vormfelde Stefan Viktor, Engelhardt Sabine, Zirk Alexandra, Meineke Ingolf, Tuchen Franziska, Kirchheiner Julia, Brockmöller Jürgen

Abstract excerpt

INTRODUCTION: According to in vitro data, torsemide (INN, torasemide) is a substrate of the genetically polymorphic enzyme cytochrome P450 (CYP) 2C9, but the impact of CYP2C9 polymorphisms on torsemide pharmacokinetics and pharmacodynamics has not been studied in humans. METHODS: A total of 36 healthy volunteers (12, 9, 1, 9, 3, and 2 carriers of CYP2C9 genotypes *1/*1 , *1/*2 , *2/*2 , *1/*3 , *2/*3 , and *3/*3...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Area Under Curve
Share to Aryl Hydrocarbon Hydroxylases

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Biotransformation

Share to Cytochrome P-450 CYP2C9

Share to Diuretics

Share to Hydroxylation

Share to Sulfonamides

Share to Uric Acid

Source

Identifiers

PMID: 15592327
DOI: 10.1016/j.clpt.2004.08.024

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide.PMID 15592327Read ↗

Genetic variation at the CYP2C locus and its association with torsemide biotransformation.Semantic proximity Read ↗

Torsemide renal clearance and genetic variation in luminal and basolateral organic anion transporters.Semantic proximity Read ↗

Torsemide metabolism by CYP2C9 variants and other human CYP2C subfamily enzymes.Semantic proximity Read ↗

Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 individuals.Semantic proximity Read ↗

Determinants of steady-state torasemide pharmacokinetics: impact of pharmacogenetic factors, gender and angiotensin II receptor blockers.Semantic proximity Read ↗

Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 genotypes.Semantic proximity Read ↗

Heritability of metoprolol and torsemide pharmacokinetics.Semantic proximity Read ↗

CYP2C9 genotype modifies activity of the renin-angiotensin-aldosterone system in hypertensive men.Semantic proximity Read ↗

UMOD Genotype-Blinded Trial of Ambulatory Blood Pressure Response to Torasemide.Semantic proximity Read ↗

The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro.Semantic proximity Read ↗

Estimation of Interindividual Variability of Pharmacokinetics of CYP2C9 Substrates in Humans.Semantic proximity Read ↗

Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.